Clinical data | |
---|---|
Other names | LY2228820 |
Routes of administration | PO |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H29FN6 |
Molar mass | 420.536 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, [1] it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor. [2]
A phase II trial for treatment of ovarian cancer has completed. [3] [4]
Clinical data | |
---|---|
Other names | LY2228820 |
Routes of administration | PO |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C24H29FN6 |
Molar mass | 420.536 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, [1] it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor. [2]
A phase II trial for treatment of ovarian cancer has completed. [3] [4]